

RESEARCH ARTICLE

Open Access



# Transcriptionally induced enhancers in the macrophage immune response to *Mycobacterium tuberculosis* infection

Elena Denisenko<sup>1</sup>, Reto Guler<sup>2,3</sup>, Musa Mhlanga<sup>4,5,6</sup>, Harukazu Suzuki<sup>7</sup>, Frank Brombacher<sup>2,3</sup> and Sebastian Schmeier<sup>1\*</sup> 

## Abstract

**Background:** Tuberculosis is a life-threatening infectious disease caused by *Mycobacterium tuberculosis* (*M.tb*). *M.tb* subverts host immune responses to build a favourable niche and survive inside of host macrophages. Macrophages can control or eliminate the infection, if acquire appropriate functional phenotypes. Transcriptional regulation is a key process that governs the activation and maintenance of these phenotypes. Among the factors orchestrating transcriptional regulation during *M.tb* infection, transcriptional enhancers still remain unexplored.

**Results:** We analysed transcribed enhancers in *M.tb*-infected mouse bone marrow-derived macrophages. We established a link between known *M.tb*-responsive transcription factors and transcriptional activation of enhancers and their target genes. Our data suggest that enhancers might drive macrophage response via transcriptional activation of key immune genes, such as *Tnf*, *Tnfrsf1b*, *Irg1*, *Hilpda*, *Ccl3*, and *Ccl4*. We report enhancers acquiring transcription de novo upon infection. Finally, we link highly transcriptionally induced enhancers to activation of genes with previously unappreciated roles in *M.tb* infection, such as *Fbxl3*, *Tapt1*, *Edn1*, and *Hivep1*.

**Conclusions:** Our findings suggest the importance of macrophage host transcriptional enhancers during *M.tb* infection. Our study extends current knowledge of the regulation of macrophage responses to *M.tb* infection and provides a basis for future functional studies on enhancer-gene interactions in this process.

**Keywords:** eRNA, Macrophages, Transcriptional enhancers, Transcriptional regulation, Tuberculosis

## Background

Tuberculosis (TB) remains a significant global threat, which causes over one million deaths each year. The causative agent of TB is *Mycobacterium tuberculosis* (*M.tb*), an intracellular pathogen that mainly persists inside host macrophages [1]. Over 30% of the world's population is infected with *M.tb*, and the infection progresses to active TB in about 5–10% of cases [1, 2]. Macrophages are one of the first lines of a host's defence against invading bacterial pathogens [3]. The complex interplay between host macrophages and *M.tb* is believed to be central to the control of infection and

defines the infection outcome [4, 5]. Macrophages are equipped with a multitude of strategies to combat *M.tb*, however, the pathogen has developed a wide range of matching resistance mechanisms, allowing it to avoid destruction and to survive and proliferate inside macrophages [5]. Hence, macrophage responses need to be tightly controlled in order to eliminate the pathogen. The lack of effective TB control systems is in part explained by significant gaps in our knowledge of the biology of *M.tb* and its interactions with the host [4]. Consequently, understanding the cellular pathways that underlie the initial infection and TB progression remains a scientific challenge directly applicable to human health.

Gene expression in eukaryotic cells is a complex process guided by a multitude of mechanisms [6]. Regulation of transcription represents one of the first layers

\* Correspondence: [s.schmeier@massey.ac.nz](mailto:s.schmeier@massey.ac.nz)

<sup>1</sup>Massey University, Institute of Natural and Mathematical Sciences, Albany, Auckland, New Zealand

Full list of author information is available at the end of the article



of gene expression control, which largely defines rapid signal-dependent expression changes [7]. Enhancers are defined as *cis*-regulatory DNA regions that activate transcription of target genes in a distance- and orientation-independent manner [8]. Nowadays, enhancers are considered major determinants of gene expression programmes required for establishing cell-type specificity and mediating responses to extracellular signals [9–11].

Enhancers are characterised by a set of distinctive features. Genomic regions surrounding enhancers carry a combination of H3K4me1 and H3K27ac histone marks that has been considered an enhancer-specific chromatin signature [12, 13]. H3K4me1 demarcates established or primed enhancers, which may or may not be active, while a combination of H3K4me1 and H3K27ac marks active enhancers [12, 13]. Enhancer regions carry multiple DNA binding sites and can recruit transcription factors and coactivators, RNA polymerase II and other proteins, such as histone acetyltransferases [9, 14, 15]. Enhancers serve as a platform for assembly of the transcription pre-initiation complex, which can result in enhancer regions being transcribed into non-coding enhancer RNAs termed eRNAs [14, 15]. This novel class of RNAs was first introduced in a genome-wide study in mouse neurons [16]. Later on, a number of studies showed that the production of eRNAs correlated with target mRNA synthesis and eRNAs could serve as robust and independent indicators of active enhancers, that are more likely to be validated *in vitro* [17–21]. Detectable eRNA levels are usually low, possibly due to their short half-life and fast degradation by RNA exosomes or their generally low transcription initiation rates [11, 22–24]. Nevertheless, eRNA transcription can be used for a genome-wide identification of active enhancers [17, 25, 26].

The dominant model of transcriptional regulation by enhancers states that it is exerted via direct physical interaction between an enhancer and a target gene promoter, mediated by DNA looping [8]. Topologically associating domains (TADs) have emerged as critical conserved units of chromatin organisation that favour internal DNA contacts, whereas regulatory interactions between TADs are limited [27, 28]. Enhancer-promoter contacts are believed to occur almost exclusively within the well-conserved TADs [29]. Notably, enhancer-promoter interactions are not limited to one-to-one contacts. Instead, an enhancer might regulate a few genes, and multiple enhancers might contribute to the activation of a gene [30]. Such enhancer redundancy was recently shown to confer phenotypic robustness to loss-of-function mutations in individual enhancers [31]. Both enhancers and enhancer-gene regulatory interactions are characterised by a remarkable tissue specificity [13, 18, 20]. Such tissue specificity is crucial for

establishing cell-type- and state-specific transcriptional programmes [9, 10]. Moreover, enhancer-gene interactions can be dynamically rewired in response to environmental stimuli, enabling fine tuning of gene expression programmes [19, 32].


Previously we used cap analysis of gene expression (CAGE) and epigenetic data to identify on large-scale transcribed enhancers (i.e. enhancers producing eRNAs) in bone marrow-derived mouse macrophages (BMDM) [33]. We have established a transcribed enhancer and target gene interactome and characterised the roles of enhancers in guiding macrophage polarisation into distinct pro- and anti-inflammatory phenotypes [33]. Here, we extended the former study to conduct the first to our knowledge genome-wide analysis of transcribed enhancers guiding BMDM response to *M.tb* infection. Our findings indicate that transcribed enhancers are extensively involved in the induction of immune genes during *M.tb* infection. We identify and characterise enhancers with induced or *de novo* acquired eRNA expression and transcription factors that likely drive these changes. We report enhancer regions that target known immune genes crucial for the host response to *M.tb*. These findings are extended by highlighting genes with previously unappreciated roles in *M.tb* infection, as their regulation by many enhancers points to their functional importance. Taken together, our findings extend the current knowledge of *M.tb*-induced immune response regulation in macrophages and provide a basis for future functional studies on enhancer-gene interactions in this process.

## Results

### Transcribed enhancers in macrophage responses to *M.tb* infection

We analysed the host transcriptional response to *M.tb* infection in mouse bone marrow-derived macrophages (BMDM) at 4, 12, 24, and 48 h post infection (see Methods). Non-infected control BMDM were profiled prior to infection (0 h) and at matched time points (4, 12, 24 and 48 h). First, we analysed overall gene expression changes and found that they were the strongest at 4 h post infection and declined with time (Fig. 1a-c). Half as many differentially expressed genes (DEGs) were detected at 12 h as at 4 h, and almost no genes were significantly differentially expressed at 24 or 48 h post infection (see Methods, Fig. 1a). We combined the DEGs from all time points into two unique lists of 1384 up- and 1604 down-regulated DEGs for further analysis.

We have previously identified 8667 actively transcribed enhancers and their target genes in mouse BMDM [33]. Here, we found that many of these enhancers acquired higher eRNA expression in response to *M.tb* infection (Additional file 1: Figure S1a). Moreover, enhancers associated with up-regulated DEGs in infected macrophages



showed an increase in eRNA expression (Additional file 1: Figure S1b, see Methods and Additional file 2: Table S1 for the list of up-regulated DEGs and their enhancers). Hence, BMDM enhancers showed an overall increase in transcriptional activity upon *M.tb* infection.

We investigated the differences in the enhancer repertoire between DEGs and non-DEGs to uncover the role of enhancers in the *M.tb* infection response. Genes with no transcribed enhancers composed 36.4% of up-regulated DEGs, whereas this percentage was significantly higher at 41.1% for down-regulated DEGs (Fisher's exact test two-sided *p*-value 0.008) (Fig. 1d). Furthermore, 41% of up-regulated DEGs, but only 34% of down-regulated DEGs were associated with more than two transcribed enhancers (Fisher's exact test two-sided *p*-value  $7.9 \times 10^{-05}$ ) (Fig. 1d). Finally, non-DEGs had the highest percentage of genes with no transcribed enhancers (45%) and the lowest percentage of genes with more than two enhancers (31%) (Fig. 1d). Hence, transcribed enhancers likely play a prominent role in up-regulation of protein-coding genes in the response to *M.tb* infection.

Previously we have shown that regulation of genes by many transcribed enhancers in BMDM was a concomitant of higher gene expression and tissue-specific function

[33]. Here, we asked whether the same properties could be observed for up-regulated DEGs, as genes most likely to be involved in the elimination of *M.tb*. Indeed, as before, we noted higher expression levels in genes associated with more enhancers in *M.tb*-infected macrophages (Fig. 1e). Gene set enrichment analysis (GSEA, see Methods) showed that DEGs with no transcribed enhancers in *M.tb*-infected macrophages were only significantly enriched (FDR < 0.05) in five KEGG pathway maps (Fig. 1f). In contrast, genes associated with more than two enhancers were significantly enriched in as many as 92 pathway maps (S2 Table), and showed a much stronger enrichment for more specific infection-related pathways (Fig. 1g, Additional file 3: Table S2) when compared to genes with no enhancers (Fig. 1f). The enrichment analysis points to the assumption that up-regulated DEGs without transcribed enhancers are functionally less related than those associated with more than two actively transcribed enhancers. Moreover, these results indicate that even within such a process-oriented set as the list of up-regulated DEGs, multiple enhancers might regulate the most highly expressed and functionally important genes. We repeated this analysis for all genes (as opposed to only DEGs) and their associated enhancers in infected macrophages and observed a similar trend

(Additional file 4: Figure S2), in agreement with our previous study [33].

We next compared our transcribed enhancers to a set of inflammation-sensitive LPS-responsive macrophage super enhancers (SEs) reported by Hah et al. [34]. Super-enhancers (or stretch enhancers) have emerged as a sub-class of particularly potent enhancers, which are associated with higher levels of enhancer-specific histone marks and regulate key cell identity genes [35, 36]. Among 2999 enhancers associated with up-regulated DEGs, 45.9% overlapped SE regions. This percentage was significantly lower at 30% for the remainder of our BMDM transcribed enhancers [33] (two-sided Fisher's exact test  $p$ -value  $< 2.2 \times 10^{-16}$ , odds ratio 1.98). Interestingly, of 880 up-regulated DEGs associated with transcribed enhancers, 477 were associated with enhancers overlapping SEs, and these DEGs showed a much stronger enrichment for immune-related functions, when compared to the 403 DEGs for which none of their associated enhancers overlapped SEs (Additional file 5: Figure S3).

Taken together, our findings indicate that the up-regulation of immune genes in BMDM upon *M.tb* infection might be largely driven by transcribed enhancers. Comparison of the three subsets of up-regulated DEGs showed the strongest enrichment for specific immune response pathways in up-regulated DEGs associated with SEs (Additional file 5: Figure S3b) and the weakest enrichment in up-regulated DEGs not associated with any transcribed enhancers (Fig. 1f), highlighting the functional importance of SEs in BMDM response to *M.tb* infection.


#### Transcriptionally induced enhancer regulation of immune genes during *M.tb* infection

We further set out to investigate a subset of enhancers that targeted up-regulated DEGs and were themselves highly transcriptionally induced upon infection. We focused on 809 DEGs that were associated to transcribed enhancers and up-regulated at 4 h post infection, as we observed the strongest transcriptional response upon infection at this time point. Of enhancers targeting these DEGs, we selected those with the highest eRNA expression at 4 h and its fold change as compared to 0 h, by requiring both these values to be in the upper quartiles of their corresponding distributions (see Methods). The derived set of 257 enhancers (further referred to as induced enhancers) was associated with 263 of 809 DEGs that were up-regulated at 4 h and associated with transcribed enhancers (Additional file 6: Figure S4, Additional file 7: Table S3). We investigated expression of the induced enhancers in other mouse tissues (Additional file 8: Table S4). Interestingly, we found that the set of enhancers showed the highest average and maximum eRNA expression, as well as the highest percentage of samples with nonzero eRNA expression in

infected macrophages (Additional file 9: Figure S5). In addition, induced enhancers were over-represented in SE regions [34] when compared to the remainder of BMDM enhancers, with 60.7% of the induced enhancers overlapping SEs as compared to 34.7% of non-induced enhancers (two-sided Fisher's exact test  $p$ -value  $< 2.2 \times 10^{-16}$ , odds ratio 2.9). These findings indicate a high specificity of the induced enhancers to the BMDM infection response and highlight the fact that they are likely key elements for driving the transcriptional responses of the macrophage upon infection.

Next, we investigated DEGs that were targeted by many induced enhancers as it stands to reason that these genes play crucial parts in the response to *M.tb*. Among the 263 DEGs, Tumour necrosis factor receptor 2 (*Tnfrsf1b*) was associated with the highest number of the induced enhancers, eight (Fig. 2). Interestingly, one of the induced enhancers (chr4:145245568..145245969, Fig. 2b) showed the second highest mean eRNA expression (28.79 TPM) at 4 h post infection among all enhancers targeting up-regulated DEGs. Tumour necrosis factor (*Tnf*), coding a ligand of *Tnfrsf1b*, was associated with three induced enhancers with mean eRNA expression of 2.4, 3.9, and 10.8 TPM at 4 h post infection. We found that induced enhancers associated with *Tnfrsf1b* were significantly over-represented in the corresponding TAD (eight induced enhancers among 38 BMDM enhancers in the TAD, hypergeometric test FDR = 0.005, see Methods). Interestingly, *Tnfrsf1b* was the only up-regulated DEG within the TAD ( $\log_2FC = 2.2$  at 4 h vs. 0 h, Fig. 2a) and encodes the Tnf receptor 2, which is known to interfere with apoptosis [37] and sensitize macrophages for Tnfr1-mediated necroptosis, a programmed form of inflammatory cell death resulting from cellular damage or infiltration by pathogens [38]. Given that all of *Tnfrsf1b*'s induced enhancers coincide with a SE, we hypothesise that the activation of the SE upon infection is driving the process in conjunction with increased eRNA expression from the induced enhancers.

Another TAD on chromosome 14 contained a group of three co-regulated DEGs (*Irg1*, *Cln5*, and *Fbxl3*) associated with six induced enhancers each, the second highest number after *Tnfrsf1b* reported above (Additional file 10: Figure S6). Moreover, among these six, the chr14:103037012..103037413 enhancer showed the highest mean eRNA expression (36.68 TPM) at 4 h post infection among all enhancers of up-regulated DEGs (Additional file 10: Figure S6b, enhancer e2). Finally, six out of 14 enhancers in the TAD were deemed induced enhancers (significant over-representation with hypergeometric test FDR = 0.001, see Methods). Of the three DEGs, *Irg1* showed the strongest induction of  $\log_2FC = 5.2$  at 4 h vs. 0 h (Additional file 10: Figure S6a). *Irg1* was recently shown to link cellular metabolism with immune



**Fig. 2** Regulation of *Tnfrsf1b* by induced enhancers. **a** Time course expression of the *Tnfrsf1b* gene. **b** Time course eRNA expression of *Tnfrsf1b*-associated induced enhancer. In **(a)** and **(b)**, data were averaged over replicates and log-transformed, error bars are the SEM (see Methods). **c** TAD containing *Tnfrsf1b* and associated enhancers; induced enhancers are shown as longer green blocks. Genes are split into two tracks based on the strand, wide orange marks denote gene promoters. DEGs significantly up-regulated at 4 h are shown in purple and their associations with enhancers are shown as thicker black connections. Super enhancers are shown as defined by Hah et al. [34] in LPS-treated macrophages. Histone marks are shown as defined by Ostuni et al. [61] in untreated and LPS-treated macrophages

defence by catalysing the production of itaconic acid, which has antimicrobial activity and inhibits the growth of *M.tb* [39]. Another gene in this TAD encodes *Cln5* ( $\log_2FC = 2$ ), which is required to recruit and activate *Rab7* [40], a GTPase essential for phagosome maturation, a process which is crucial for microbial killing by macrophages and which can be disrupted by *M.tb* as a part of its survival strategy [41–43]. The link between highly induced enhancers and *Irg1* and *Cln5* points to biological processes important for the host response that might be driven by transcribed enhancers, while the immune functions of *Fbxl3* ( $\log_2FC = 1.4$ ) are yet to be elucidated.

Induced enhancers were significantly over-represented with  $FDR < 0.05$  in four more TADs, which we further investigated as potentially important *M.tb*-responsive genomic regions (Additional file 11: Table S5). One of the TADs ( $FDR = 0.001$ , five induced enhancers among eight BMDM transcribed enhancers, Additional file 12: Figure S7) is as large as 1.2 Mb and contains multiple genes, however, only *Hilpda* (*Hig2*) was differentially expressed and up-regulated at 4 h ( $\log_2FC = 6$ , Additional file 12: Figure S7a). *Hilpda* is induced in hypoxia and is crucial to lipid accumulation in macrophages [44], which provides a favourable environment for

dormant *M.tb* and might, thus, contribute to *M.tb* survival within the host [45]. Similarly, *Itgb8* was the only up-regulated DEG ( $\log_2FC = 7.1$ ) in another TAD with five induced enhancers among 14 BMDM transcribed enhancers (FDR 0.011, Additional file 13: Figure S8). Although specific roles of *Itgb8* in *M.tb* infection response have not yet been established, integrin alpha(v)beta8 is known to activate TGF-beta [46], an important mediator of susceptibility to *M.tb* [47].

A TAD with four induced enhancers among eight BMDM transcribed enhancers (FDR = 0.012) contains three DEGs up-regulated at 4 h post infection (Additional file 14: Figure S9). *Cd38* and *Bst1* (*Cd157*) are homologous NAD(+) metabolic enzymes up-regulated by *Tnf* [48], and *Cd38* was shown to be involved in phagocytosis [49] and response to intracellular pathogen *Listeria monocytogenes* [50] in mouse macrophages. The role of the third gene in that TAD, transmembrane protein *Tapt1*, remains to be elucidated.

Finally, a TAD with five induced enhancers among 17 BMDM transcribed enhancers (FDR = 0.02) covers four DEGs *Ccl3*, *Ccl4*, *Ccl9*, and *Wfdc17* (Additional file 15: Figure S10). *Ccl3* and *Ccl4* are macrophage-derived inflammatory chemokines that induce chemotactic mobilization of immune cells [51], while *Wfdc17* might have the opposite function decreasing production of pro-inflammatory cytokines [52], and the function of *Ccl9* in macrophage infection response remains to be uncovered [51].

Taken together, these examples highlight six TADs (Additional file 11: Table S5), located on six different chromosomes, which show strong responses to *M.tb* infection and contain genes with both known and previously unappreciated roles in *M.tb* infection. These genes are under the control of multiple *M.tb* induced enhancers, which might be essential for contributing to the genes' activation states.

To get further insights into the capacity of induced enhancer regulation during the response to *M.tb* infection, we investigated target DEGs of induced enhancers that were significantly enriched in particular biological pathways (Additional file 6: Figure S4b). The *Tnf* signalling pathway showed the strongest enrichment for induced enhancer-regulated DEGs and included 18 DEGs up-regulated at 4 h and associated with the induced enhancers. Among these genes, in addition to *Tnfrsf1b* reported above, we identified *Tnf* itself, *Tnf* signalling pathway mediator *Traf5* and multiple effector genes targeted by induced enhancers (Additional file 16: Table S6). *Tnf*-alpha receptors are known to trigger the NF-kB signalling pathway, which was also enriched for DEGs regulated by induced enhancers, including receptors *Cd14* and *Cd40*, ligand *Il1b*, and TFs of canonical NF-kB signalling, *Nfkb1* and *Rela* (Additional file 16: Table S6).

'Tuberculosis' KEGG pathway map comprised five signal transduction mediators, *Irak2*, *Jak2*, *Malt1*, *Ripk2*, and *Src*, regulated by induced enhancers (Additional file 16: Table S6). In addition, induced enhancers target the *Eea1* gene, which is known to be involved in phagosome maturation, a process necessary for killing of bacteria within phagosomes [53] (Additional file 16: Table S6). Notably, genes encoding negative regulators of the listed signalling pathways, *Nfkbia*, *Tnfaip3*, and *Socs3*, were also associated with one to five induced enhancers (Additional file 16: Table S6), and showed up-regulation.

#### Transcriptionally induced enhancers are enriched for immune transcription factor binding sites

Transcription factor (TF) binding motif analysis was performed to uncover TFs potentially involved in the transcriptional activation of induced enhancers. We identified twelve significantly over-represented motifs of TFs that were differentially expressed and up-regulated at 4 h post infection (see Methods, Table 1). Five of these motifs belong to the AP-1 family of TFs, among which the highest expressed one was *Junb*, recently reported to be an important regulator of immune genes in macrophages treated with LPS [54]. Interestingly, a negative regulator of AP-1, *Jdp2*, was also among the significantly over-represented motifs, although it was found only in 20.6% of the induced enhancers. Three motifs of NF-kB family were identified, among which *Rela* was reported above to be itself regulated by the induced enhancers, potentially forming a positive feedback loop. For another TF identified here, *Irf1*, we have previously reported that in association with *Batf2* ( $\log_2FC = 2.7$ ) it induced inflammatory responses in *M.tb* infection [55]. Both AP-1 and NF-kB families of TFs, as well as *Irf1*, play important roles in macrophages and can be triggered by a range of infection response receptors including Toll-like and Nod-like receptors [56, 57]. *Rbpj*, which showed the second strongest motif over-representation, is a key TF of canonical Notch signalling pathway, which is known to be activated by Toll-like receptor signalling pathways [58]. Finally, *Nfe2l2* (*Nrf2*) regulates cytoprotective genes that enhance cell survival and was shown to increase phagocytic ability of macrophages and to improve anti-bacterial defence [59, 60].

Importantly, 89.1% of the 257 induced enhancers considered here carry at least one of the twelve motifs, and these enhancers target 95.1% of the 263 up-regulated DEGs (Table 2). Among the motifs, AP-1 family members covered the largest percentages of the induced enhancers and their target genes, followed by the NF-kB family and *Rbpj* TF, highlighting their importance in enhancer regulation of *M.tb* response. We compared this TF regulation of protein-coding genes via enhancers to TFs that bind directly to the promoters of the 263

**Table 1** TF motifs over-represented in the induced enhancers

TF Motif	# overlapping enhancers	Expression, TPM	log <sub>2</sub> FC	FDR
FOSL1::JUNB	118 (45.9%)	19.4 / 523.7	5.4 / 2.6	2.7e-03 / 1e-04
RBPJ	117 (45.5%)	295.7	1.8	7.3e-03
REL	96 (37.4%)	165.3	3	4.3e-06
FOSL2::JUNB	91 (35.4%)	81.2 / 523.7	2.4 / 2.6	1.2e-06 / 1e-04
IRF1	88 (34.2%)	1099.8	2.8	1.5e-04
RELA	87 (33.9%)	309	1.7	1e-06
JUNB	84 (32.7%)	523.7	2.6	1e-04
FOSL1	80 (31.1%)	19.4	5.4	2.7e-03
FOSL2	80 (31.1%)	81.2	2.4	1.2e-06
Nfe2l2	54 (21%)	684	1.5	2.4e-03
JDP2	53 (20.6%)	67.7	2.9	4.8e-04
NFKB2	28 (10.9%)	496.3	2.7	2.5e-04

Columns show TF motif name, number and percentage of overlapping enhancers among the induced enhancers, average expression of the corresponding TF(s) in infected BMDM at 4 h, fold change and FDR of differentially expressed test for the corresponding TF(s) in infected BMDM at 4 h versus non-infected control at 0 h. Motifs were retained for TFs with significant up-regulation at 4 h

up-regulated DEGs (see Methods). In the promoters, *Irf1*, as well as AP-1, and NF-κB families were similarly significantly over-represented, whereas, *Rbpj*, *Nfe2l2* and *Jdp2* were not deemed significant and, thus, might be specific to the transcriptionally induced enhancers. Taken together, these findings link *M.tb*-perturbed signalling pathways and their key TFs to transcriptional activation of the induced enhancers, which in turn activate their immune target DEGs.

#### A subset of enhancers is transcribed de novo upon *M.tb* infection

Interestingly, among 257 induced enhancers we found 17 enhancers that showed zero eRNA expression in all of the 22 non-infected macrophage samples. Hence, transcription of these enhancers was specifically acquired de novo in macrophages upon *M.tb* infection. These enhancers were associated with 31 of the 263 DEGs under investigation, which included *Hilpda*, *Il1b*, *Itgb8*, *Jak2*, *Src*, and *Tnfrsf3* genes, reported above. We


set out to further investigate in more detail the phenomenon of de novo transcription at enhancers.

We focused on enhancers that were transcriptionally silent in naïve BMDM, but acquired transcriptional activity de novo in *M.tb*-infected macrophages (further referred to as acquired enhancers). We hypothesized that such enhancers might either loop towards their target promoters in non-infected macrophages without being transcriptionally active, or form a novel DNA loop upon infection (Fig. 3a-b). In total, we identified 356 acquired enhancers (see Methods). Their eRNA expression was the highest at 4 and 12 h post infection and declined with time (Fig. 3c, left panel), in agreement with the DEG expression reported above. Notably, overall expression of acquired enhancers in infected macrophages was lower than that of induced enhancers (median of 0.23 TPM versus 1.73 TPM at 4 h). However, similarly to induced enhancers, acquired enhancers showed the highest expression in infected macrophages when compared to other mouse tissues (Additional file 17: Figure S11). Thus, the transcriptional activity of acquired enhancers

**Table 2** TF-mediated regulation of genes via induced enhancers

TF Motifs	# overlapping enhancers	# target DEGs
AP-1 (FOSL1::JUNB, FOSL2::JUNB, JUNB, FOSL2, FOSL1)	128 (49.8%)	180 (68.4%)
NF-κB (REL, RELA, NFKB2)	117 (45.5%)	157 (59.7%)
RBPJ	117 (45.5%)	160 (60.8%)
IRF1	88 (34.2%)	126 (47.9%)
Nfe2l2	54 (21%)	86 (32.7%)
JDP2	53 (20.6%)	92 (35%)
Total (12 motifs)	229 (89.1%)	250 (95.1%)

Columns show individual TF motifs or their groups, number and percentage of overlapping enhancers among the induced enhancers, number and percentage of DEGs targeted by these enhancers among the 263 DEGs up-regulated at 4 h and associated with the induced enhancers



**Fig. 3** Enhancers that acquire transcriptional activity de novo upon *M.tb* infection. **a** and **b** show presumable changes in gene regulation upon infection: **(a)** In non-infected macrophages, a transcriptionally inactive enhancer loops towards its target gene, **(b)** Upon *M.tb* infection, the enhancer acquires transcriptional activity; an additional loop is formed de novo for another acquired transcribed enhancer; the gene expression is induced. **c** eRNA expression of 356 acquired enhancers (left) and their 526 target genes (right); dashed line shows median gene expression prior to the infection, expression in TPM was averaged across replicates, *p*-values of Wilcoxon two-sided rank sum tests are shown. **d** Top 5 KEGG pathway maps with the lowest FDR enriched for 526 target genes of the acquired enhancers; next to the bars are the numbers of genes in the KEGG term covered by our gene list; dashed line indicates FDR = 0.05

demonstrated high specificity to the response of BMDM to infection.

We further compared acquired enhancers to genomic regions carrying H3K4me1 and H3K27ac histone marks, which demarcate pre-established enhancer regions and active enhancers, respectively. We used data from Ostuni et al. [61] for untreated and LPS-treated macrophages. Of 356 acquired enhancers, 83.1 and 99.2% overlapped H3K4me1-enriched regions in untreated and LPS-treated macrophages, respectively, indicating that most acquired transcribed enhancers might be established in naïve macrophages, prior to infection. Unexpectedly, as much as 63.8% of acquired enhancers overlapped H3K27ac-enriched regions in untreated macrophages. However, this percentage was higher at 86% in LPS-treated macrophages, and the corresponding H3K27ac ChIP-seq peaks were stronger

enriched in LPS-treated as compared to untreated macrophages (Additional file 18: Figure S12).

#### Acquired enhancers in the regulation of immune genes during *M.tb* infection

The acquired enhancers in infected macrophages were associated with 526 genes. The associated genes showed an overall increased expression upon *M.tb* infection (Fig. 3c, right panel) and, importantly, a strong enrichment for immune response-related functions (Fig. 3d). For further analyses, we sub selected target DEGs that showed up-regulation at 4 h post infection (251 genes, 47.7%, Additional file 19: Table S7).

First, we investigated enhancer-gene associations and found that, at maximum, a DEG was associated with six acquired enhancers. We identified five such genes (*Hivep1*,

*Itgb8*, *Pla2g4a*, *Ptgs2*, and *Tnfrsf3*). Among the genes, *Pla2g4a* and *Ptgs2* were co-regulated by the same set of acquired enhancers within a TAD (Additional file 20: Figure S13). Both genes are known to be involved in arachidonic acid metabolism, one of the regulators of cell death, and to play a role in infection responses [62]. While *Pla2g4a* showed a moderate induction of  $\log_2FC = 2.9$ , expression of *Ptgs2* was induced dramatically with  $\log_2FC = 11.5$  at 4 h post infection (Additional file 20: Figure S13a), hinting at its importance during infection.

The strongest induction of  $\log_2FC = 12.3$  at 4 h was observed for endothelin (*Edn1*), a DEG associated with five acquired enhancers (Additional file 21: Figure S14). *Edn1* is a well-known vascular regulator; however, its particular roles in infectious diseases including tuberculosis are only beginning to be elucidated [63]. *Edn1* is co-regulated with DEG *Hivep1*, a transcriptional regulator for which the precise function in infected macrophages is unknown (Additional file 21: Figure S14).

All of *Pla2g4a*, *Ptgs2*, *Edn1*, and *Hivep1* genes were additionally associated with other enhancers, which were not classified as acquired enhancers. Among those, *Edn1* and *Hivep1* were associated with one enhancer that was deemed induced in our study (Additional file 21: Figure S14c), while *Pla2g4a* and *Ptgs2* were associated with four such induced enhancers (see Additional file 20: Figure S13c for eRNA expression of one of them). These enhancers, in contrast to the acquired ones, showed nonzero (although very low) eRNA expression in non-infected macrophages. Notably, in infected macrophages these induced enhancers had a higher expression than the acquired enhancers associated to the same genes (Additional file 20: Figure S13 and Additional file 21: Figure S14). Thus, up-regulation of DEGs *Pla2g4a*, *Ptgs2*, *Edn1*, and *Hivep1* could not be attributed exclusively to the activity of the acquired enhancers.

We further asked whether any of the 251 up-regulated DEGs were associated exclusively with acquired enhancers. We identified 22 such genes regulated by a total of 18 acquired enhancers. However, in most cases, we observed either low or inconsistent eRNA expression among replicates. Hence, our data could not reliably infer up-regulated DEGs driven exclusively by acquired enhancers. Moreover, the 251 DEGs were associated on average with 1.6 acquired enhancers and 6.1 other enhancers, not classified as acquired. These findings suggest that upon *M.tb* infection, de novo transcription at enhancers targeting up-regulated DEGs is acquired in addition to already established transcriptionally active enhancers.

TF binding motif analysis of the acquired enhancers showed overall similar results to that of the induced enhancers, except for *Irf1* motif which was over-represented only in induced enhancers, and three

TF motifs over-represented only in acquired ones. Among these, a motif for *Stat3*, a TF known to be involved in *M.tb* infection response [64], overlaps 36.2% of the acquired enhancers. Macrophage-restricted TF *Tfec* with an overlap of 35.7% has been reported as an important regulator of IL-4 inducible genes in macrophages but was also up-regulated in response to LPS treatment [65]. Finally, the *Srebf2* motif overlaps 25.3% of the acquired enhancers. Interestingly, this TF is a host gene of miR-33, a miRNA induced in macrophages by *M.tb* to inhibit pathways of autophagy, lysosomal function and fatty acid oxidation to support *M.tb* intracellular survival [66]. Taken together, these results uncover a novel role of these TFs in the response to *M.tb* infection in BMDM.

## Discussion

Studies in multiple cell types unravelled the fundamental importance of enhancer regions as DNA regulatory elements, however, our current understanding of these elements remains incomplete. High tissue specificity of enhancers is a major hurdle towards establishing a comprehensive catalogue of the full enhancer population [9, 10]. Moreover, emerging evidence indicates that enhancers selectively act in a stimuli- or condition-specific manner [19, 32]. Enhancers often mediate cell-type-specific processes [32]. Previously we reported on the role of transcribed enhancers in macrophage activation and polarisation towards pro- and anti-inflammatory phenotype [33]. Another recent study linked a specific class of enhancers to the immune response in human [67]. Hence, we hypothesised that enhancers might also regulate macrophage response to the infection with intracellular pathogens such as *M.tb*. To investigate this possibility, here we analysed *M.tb*-induced changes of gene expression and enhancer activity in macrophages. Our results suggest that transcribed enhancers have a strong influence in the infection response and mediate up-regulation of many important immune protein-coding genes. The strongest macrophage response to *M.tb* was observed at 4 h post infection, hence, we elected to focus on DEGs up-regulated at this time point and to analyse their associated enhancers. We characterised highly transcriptionally induced enhancers and showed that many genes acquired de novo transcribed enhancers upon *M.tb* infection. We reported enhancers targeting known immune genes crucial for the genetic response of the host to *M.tb* and highlighted transcription factors that are likely regulating these enhancers. These findings were extended by highlighting particular chromosomal domains carrying groups of highly transcriptionally induced enhancers and genes with previously unappreciated roles in *M.tb* infection.

Previously we have demonstrated that regulation by many enhancers was a concomitant of higher gene expression and tissue-specific functions [33], in agreement with a model of additive enhancer action [8, 68]. Unexpectedly, here we report a similar observation for a highly function-specific set of DEGs up-regulated upon *M.tb* infection. Furthermore, our results indicate that activation of SEs might have a prominent role in regulating macrophage responses to the pathogen, in line with current views of SEs as genomic regions of extreme importance for the regulation of key genes involved in cell-specific processes and responses [35, 36].

Several studies have reported on enhancers that were activated de novo upon stimuli [61, 69]. These might represent a particularly functionally important class of enhancers responsible for establishing stimuli-specific gene expression programmes. Ostuni et al. [61] uncovered a set of latent enhancers that lacked any enhancer characteristics in naïve mouse macrophages, but gained active enhancer marks in response to stimulation. Similarly, Kaikkonen et al. [69] identified enhancers activated de novo in mouse macrophages stimulated with TLR4 agonist and, interestingly, suggested that eRNA transcription might precede H3K4me1 deposition. In this study, we asked whether any enhancers were non-transcribed in naïve macrophages and acquired de novo eRNA transcription upon *M.tb* infection. Interestingly, in contrast to Ostuni et al. [61] and Kaikkonen et al. [69], we found that most of the acquired enhancers might be already marked with H3K4me1 (hence, primed) in naïve macrophages. The remaining 60 of 356 enhancers might acquire both, a H3K4me1 mark and transcriptional activity, upon infection. In agreement with this idea, all 60 enhancers carried H3K4me1 histone marks in LPS-treated macrophages. Moreover, we found that 63.8% of acquired enhancers overlap H3K27ac histone marks in untreated macrophages. This is an unexpectedly large percentage, since H3K27ac is believed to demarcate active enhancers. One possible explanation is that H3K27ac-marked enhancers might have a spectrum of activation states, including those with and without eRNA production. In agreement with this hypothesis, we observe a much stronger H3K27ac enrichment in regions overlapping acquired enhancers in LPS-treated as compared to untreated macrophages. Hence, the strength of H3K27ac enrichment rather than the presence or absence of this histone mark could demarcate actively transcribed enhancers.

Our findings indicate that up-regulated genes in *M.tb*-infected macrophages might acquire de novo transcribed enhancers in addition to already established actively transcribed enhancers. We hypothesise that acquired enhancers might be involved in regulating their target genes via at least two different mechanisms. First,

activation of acquired enhancers might involve considerable rearrangement of chromatin to allow formation of novel DNA loops between enhancers and their target promoters. Indeed, examples of stimuli-driven dynamical changes in chromatin conformation in mouse macrophages were reported recently [70]. The second hypothetical mechanism would involve the transcriptional activation of enhancers within pre-established chromatin loops. We found that acquired enhancers are often surrounded by other enhancers that are transcribed in naïve macrophages, including *M.tb*-induced enhancers. The fact that these enhancers, at least in some cases, are located close to each other and within SEs points to a hypothetical regulatory mechanism that involves an expansion of active enhancer regions. For instance, a few individual enhancers within a SE might be primed and generate low levels of eRNAs in naïve macrophages. Upon *M.tb* infection, these individual enhancers could serve as 'seeds' to enable broader neighbouring regions to acquire enhancer histone marks and stronger eRNA transcription. Such a phenomenon has been described in mouse stem cells, where seed enhancers were shown to expand into SEs [71]. Similarly, a seed enhancer required for activation of a SE has been reported in mammary glands [72]. However, the associated mechanisms and abundances of such seed enhancers remain to be elucidated.

We separately considered two overlapping subsets of enhancers: acquired and induced enhancers. The identification was based on eRNA expression levels before and after *M.tb* infection. However, it is important to note that there is a narrow margin separating these classes, which is influenced by the limits of expression versus noise detection by CAGE and by our sample composition. In other settings, the composition of these classes might differ from our results. For instance, some induced enhancers showed very low (close to zero) eRNA expression in non-infected macrophages, which could be, alternatively, attributed to transcriptional noise.

Signalling pathways regulating macrophage responses to infection have been extensively studied [1, 5, 73], and here we report *M.tb*-induced enhancers that might activate these pathways. We find that induced enhancers might extensively control Tnf and NF- $\kappa$ B signalling pathways by targeting their components, starting from receptors (*Cd14* and *Cd40*) and ligands (*Il1b*, *Tnfrsf1b*, *Tnf*), through mediators (*Traf5*, *Irak2*, *Jak2*, *Malt1*, *Ripk2*, and *Src*), ending with TFs (*Nfkb1* and *Rela*) and numerous pathway effectors. These pathways are known to be activated upon macrophage recognition of *M.tb* and play central roles in shaping immune responses, as they mediate production of pro-inflammatory cytokines and chemokines, and regulate apoptosis [74, 75]. Interestingly, induced enhancers might also control negative

feedback regulators of these pathways (*Nfkbia*, *Tnfaip3*, and *Socs3*), which might implicate induced enhancers in terminating immune responses.

As important examples, we highlighted genes regulated by multiple induced or acquired enhancers. We also reported on TADs, where induced enhancers were over-represented, as these chromosomal regions could be considerably affected by *M.tb*. Notably, in this manner we highlighted a group of genes that might be decisive in *M.tb* death versus survival balance via different mechanisms. Knowledge on the regulation of these genes is extremely important for understanding *M.tb* survival strategies and development of novel treatments. Genes with known immune functions are often co-regulated with DEGs with previously unappreciated functions in *M.tb* infection response (such as *Fbxl3*, *Tapt1*, *Edn1*, and *Hivep1*), and these DEGs are, thus, good candidates for further functional studies.

*M.tb* is known to control macrophage cell death pathways, and existing evidence suggests that *M.tb* might induce necroptosis, which facilitates the spread of the pathogen [76]. Here, we found that induced enhancers might be involved in modulating macrophage cell death. For instance, *Tnf* is targeted by three induced enhancers, and might activate both apoptosis and necroptosis via Tnf-signalling pathway, depending on expression of other factors [76]. Activation of a DEG *Tnfrsf1b*, associated with eight induced enhancers, is known to interfere with apoptosis and sensitise macrophages for Tnfr1-mediated necroptosis [37, 38]. In addition, *Pla2g4a*, targeted by four induced enhancers, is involved in metabolism of arachidonic acid, a precursor of lipoxins, leukotrienes, and prostaglandins, lipid mediators which regulate apoptotic/necroptotic balance [62, 77]. *Il1a* and *Il1b* DEGs, co-regulated by four induced enhancers, stimulate production of prostaglandins, linked to necroptosis suppression [77].

Finally, we investigated the transcriptional regulation of induced and acquired enhancers. We identified TFs with binding sites significantly over-represented in these enhancer sets. Importantly, most of these TFs are known to be activated in response to infection, for instance, via Toll-like and Nod-like receptors upon recognition of the pathogen. These findings propose a mechanistic link between *M.tb* infection and transcriptional activation of enhancers that mediate up-regulation of immune genes. Interestingly, we found that most of the TFBS motifs over-represented in induced enhancers were also over-represented in promoters of their target genes, indicating co-regulation of enhancer and promoter transcription by the same cellular machinery.

Macrophages are versatile immune cells, and a spectrum of their phenotypes has been observed, including distinct populations of tissue resident macrophages

[78]. In vivo, host alveolar macrophages, which are functionally different from BMDM, are infected by *M.tb*. While alveolar macrophages can be easily isolated from mice, the yield is low for a full-scale transcriptomic analysis. In contrast, BMDMs can be expanded to large numbers [79]. In addition, BMDM are greatly adherent, homogenous and highly phagocytic [80]. Matured BMDM easily respond to external cytokine stimulation such as IFN- $\gamma$  and can kill mycobacteria [81]. Although there are some drawbacks of using BMDM as a model system of infection in particular for drug efficacy studies [82], the advantages have also been appealing to other researchers, and BMDM have been used as the primary macrophage model in many immunological transcriptomic studies [79, 83–85]. However, as a consequence of using naïve BMDM as a model, responses observed in our data might differ from host alveolar macrophage responses. Furthermore, some of the transcriptomic changes analysed here could be triggered not by the contact with *M.tb* per se, but rather by other *M.tb* response-associated events, such as cytokine secretion. Future studies of *M.tb* infection in combination with cytokine stimulation could help to further characterise this. In addition, the current study is limited by a missing independent validation of enhancer expression. This could be facilitated in future studies by using for example 5'RACE and ChIP-seq approaches in infected macrophages.

One of the crucial areas of TB research is the development of novel strategies for host-directed therapies, which can stimulate host antimicrobial pathways and suppress host subversion by *M.tb* [86, 87]. Targeting disease-specific enhancers has been investigated as a therapeutic approach in cancer and autoimmune diseases [88, 89]. This study suggests that both acquired and induced enhancers regulate immune genes, which are crucial for *M.tb* survival versus elimination balance. Moreover, transcriptional activity of these enhancers is characterised by a high macrophage- and infection-specificity. Hence, these enhancers are likely good candidate regulatory genomic regions for targeted manipulation of macrophage responses to *M.tb* infection.

## Conclusions

*M.tb* triggers extensive changes in macrophage gene expression programmes that are decisive for the infection outcome, yet the associated regulatory mechanisms remain largely unknown. This is the first to our knowledge study of the role of transcribed enhancers in macrophage response to *M.tb* infection. It extends current understanding of the regulation of *M.tb* responses by linking *M.tb*-responsive transcription factors to activation of transcribed enhancers, which, in turn, target protein-coding immune genes upon infection. Given the increasing promise for enhancer- and chromatin-directed therapy, this work

paves the way for further targeted studies towards a host-directed therapy and novel tuberculosis treatments.

## Methods

### Bone marrow-derived macrophage (BMDM) generation

BALB/c mice were purchased from Jackson Laboratories and bred at the Research Animal Facility, University of Cape Town, South Africa. Mice were anaesthetized with Xylazine (10 mg/kg) + Ketamine (100 mg/kg) via i.p. injection in a total volume of 200  $\mu$ l. Anaesthetized mice were then sacrificed by cervical dislocation. BMDM were generated from 8 to 12 week old male BALB/c mice as described previously [90].

### Ethics statement

Mice were sacrificed in accordance with the Animal Research Ethics of South African National Standard (SANS 10386:2008) and University of Cape Town of practice for laboratory animal procedures. The protocol (Permit Number: 012/036) was approved by the Animal Ethics Committee, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

### *M.tb* infection

BMDM were plated in 6-well plates (Nunc, Denmark) at  $2 \times 10^6$  cells per well and left to adhere for 40 h. BMDM were then infected with log phase *M.tb* HN878 (MOI = 5) for 4 h. The choice of MOI was defined by the fact that at a higher MOI (10:1), BMDM died at the late stage of infection with HN878 (120 h post infection). At lower MOI (1:1) not all BMDM were infected creating a heterogeneous population consisting of un-infected and *M.tb*-infected BMDM. Therefore, we have opted for a MOI of (5:1) to enable a homogenous population of infected BMDM. This is in line with former studies on transcriptional response of BMDM infected with *M.tb* HN878, where the same MOI of (5:1) was utilized [91].

Cells were washed to remove extracellular mycobacteria and replenished with fresh medium containing 10  $\mu$ g/ml of gentamycin. At 0, 4, 12, 24 and 48 h, *M.tb*-infected and non-infected BMDM were lysed with 700  $\mu$ l of Qiazol (Qiagen, Valencia, CA, USA) for RNA extraction. Total RNA was prepared using miRNAeasy kit (Qiagen, Valencia, CA, USA) and concentration and quality of each RNA samples was verified as described previously [90]. All *M.tb* infection experiments were performed at the Biosafety Level 3 (BSL-3) laboratory, Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, South Africa.

### Data

Macrophage samples were profiled by us using cap analysis of gene expression (CAGE) as described in Roy et al. [92]. Samples used in this study include three

biological replicates per time point profiled at 4, 12, 24, and 48 h post infection in *M.tb* HN878-infected and control macrophages (except for 48 h infected samples, where two biological replicates were available). In addition, four biological replicates were profiled prior to infection at 0 h and six more samples were profiled during macrophage cultivation before this time point.

Mouse genome assembly mm10 and Ensembl gene models version 75 were used [93]. CAGE-derived tag counts were normalized to tags per million (TPM) using TMM normalization [94].

Data were processed, including identification of enhancer regions and enhancer-gene associations, as described in Denisenko et al. [33]. Briefly, enhancers were defined following the strategy of Andersson et al. [17] as bidirectionally transcribed 401 bp regions, and further were required to overlap ChIP-seq-derived H3K4me1 histone marks [61]. Enhancer-gene associations were established by selecting enhancers and promoters which were located within the same TAD [28] and showed positive Spearman's correlation coefficient of expression in macrophages with  $FDR < 10^{-4}$  (Benjamini-Hochberg procedure [95]). Of all enhancer-gene associations established in [33], we here sub selected only those with a positive Spearman's correlation of expression specifically in the infected macrophage samples.

### Differential expression analysis

Differential gene expression analyses were performed using the exact test implemented in edgeR [94]. Four macrophage samples profiled prior to the infection (0 h) were used as a control. The *p*-values were adjusted for multiple hypothesis testing using the Benjamini-Hochberg procedure [95].  $FDR \leq 0.05$  and  $\log_2$  fold change  $> 1$  ( $< -1$ ) thresholds were used to select differentially expressed up- (down-) regulated genes (DEGs).

### Gene set enrichment analysis (GSEA)

KEGG pathway maps [96] were used as a set of biological terms for GSEA. We used the hypergeometric distribution to calculate the probability of obtaining the same or larger overlap between a gene set of interest and each biological term [97]. Derived *p*-values were corrected for multiple testing using Benjamini-Hochberg procedure [95]. As a background gene list, a set of 22,543 Ensembl protein-coding genes (version 75) was used [93].

### Overlaps with ChIP-seq data

We used ChIP-seq data for H3K4me1 and H3K27ac histone marks profiled in untreated and LPS-treated macrophages by Ostuni et al. [61] (Gene Expression Omnibus accession GSE38379). Genomic coordinates of

significant ChIP-seq peaks were converted from mm9 to mm10 using the liftOver program [98].

### Transcription factor binding analysis

Transcription factor (TF) binding profiles were downloaded from JASPAR database, 7th release, 2018 [99]. The Clover program [100] was used for identification of statistically over-represented motifs. Enhancer regions were tested against three background DNA sets, as previously defined by us [33]: 1) the whole set of transcribed mouse enhancers; 2) a subset of these enhancers not transcribed in macrophages; 3) a set of random genomic regions excluding gaps, repeated sequences, Ensembl coding regions, and the transcribed mouse enhancers. Promoter regions were tested against the following three sets: 1) all promoters expressed in mouse tissues; 2) a subset of those not expressed in macrophages; 3) the same set of random genomic regions as used for enhancers. Promoters were used as defined in [33] and were extended by 500 bp upstream and downstream. Motifs with  $p$ -value  $< 0.01$  for each of the three background sets were selected as significantly over-represented. TFs that were significantly differentially expressed and up-regulated at 4 h post infection when compared to 0 h were retained.

### *M.tb*-induced and acquired enhancers

*M.tb*-induced enhancers were selected among those associated with DEGs up-regulated at 4 h post infection. Mean eRNA expression for these enhancers at 4 h and its fold change compared to 0 h were calculated. Enhancers were defined as induced, if both these values were in the upper quartiles of their corresponding distributions. Acquired enhancers were defined as those with no detectable eRNA expression in each of 22 non-infected BMDM samples, and nonzero expression in any of the infected macrophage samples.

### TADs enriched for enhancers

Genomic coordinates of TADs in mouse embryonic stem cells were obtained from a study by Dixon et al. [28] and were converted from mm9 to mm10 using the liftOver program [98]. To uncover chromosomal domains that might be important in macrophage response to *M.tb*, we identified TADs that were significantly enriched for induced enhancers. A hypergeometric test was performed for each TAD by comparing the total number of BMDM enhancers in that TAD to the subset of those deemed induced. The  $p$ -values for 1228 TADs were corrected for multiple hypothesis testing using Benjamini-Hochberg procedure [95]. TADs with  $FDR < 0.05$  were selected as significantly enriched for induced enhancers.

## Additional files

- Additional file 1: Figure S1.** Many enhancers respond to *M.tb* infection with increased eRNA expression. (PDF 80 kb)
- Additional file 2: Table S1.** A list of DEGs up-regulated at any time points, with their associated enhancers in infected macrophages. (XLSX 282 kb)
- Additional file 3: Table S2.** KEGG pathway maps significantly enriched for up-regulated DEGs associated with more than two transcribed enhancers. (XLSX 12 kb)
- Additional file 4: Figure S2.** Higher number of associated enhancers is a concomitant of higher gene expression and immune functions in infected macrophages. (PDF 211 kb)
- Additional file 5: Figure S3.** Up-regulated DEGs associated with super enhancers show more infection-specific functions. (PDF 150 kb)
- Additional file 6: Figure S4.** 257 induced enhancers associated with 263 DEGs up-regulated at 4 h post infection. (PDF 152 kb)
- Additional file 7: Table S3.** Induced enhancers with associated target DEGs up-regulated at 4 h post infection. (XLSX 38 kb)
- Additional file 8: Table S4.** A full list of non-macrophage mouse samples split by tissue. Tissues with at least ten samples were considered separately, the rest of the samples were combined together into an 'Others' category. (XLSX 32 kb)
- Additional file 9: Figure S5.** Expression of the induced enhancers in mouse tissues. (PDF 123 kb)
- Additional file 10: Figure S6.** Regulation of *Irg1*, *Cln5*, and *Fbxl3* genes. (XLSX 12 kb)
- Additional file 11: Table S5.** TADs enriched for induced enhancers. (XLSX 9 kb)
- Additional file 12: Figure S7.** Regulation of *Hilpda* gene. (PDF 177 kb)
- Additional file 13: Figure S8.** Regulation of *Itgb8* gene. (PDF 163 kb)
- Additional file 14: Figure S9.** Regulation of *Cd38*, *Bst1*, and *Tapt1* genes. (PDF 175 kb)
- Additional file 15: Figure S10.** Regulation of *Ccl9*, *Ccl3*, *Ccl4*, and *Wfdc17* genes. (PDF 202 kb)
- Additional file 16: Table S6.** Three selected KEGG pathway maps enriched for DEGs regulated by induced enhancers. Corresponding DEGs and induced enhancers are listed along with correlation coefficient and  $p$ -value. (PDF 184 kb)
- Additional file 17: Figure S11.** Expression of the acquired enhancers in mouse tissues. (PDF 125 kb)
- Additional file 18: Figure S12.** H3K27ac ChIP-seq peaks. (PDF 49 kb)
- Additional file 19: Table S7.** Acquired enhancers with associated target genes up-regulated at 4 h post infection. (XLSX 33 kb)
- Additional file 20: Figure S13.** Regulation of *Pla2g4a* and *Ptgs2* genes. (PDF 191 kb)
- Additional file 21: Figure S14.** Regulation of *Edn1* and *Hivep1* genes. (PDF 158 kb)

### Abbreviations

BMDM: Bone marrow-derived macrophages; CAGE: Cap analysis of gene expression; ChIP-seq: Chromatin immunoprecipitation followed by sequencing; DEG: Differentially expressed gene; FC: Fold change; FDR: False discovery rate; GSEA: Gene set enrichment analysis; *M.tb*: *Mycobacterium tuberculosis*; MOI: Multiplicity of infection; SE: Super enhancer; TAD: Topologically associating domain; TB: Tuberculosis; TF: Transcription factor; TFBS: Transcription factor binding site; TPM: Tags per million

### Acknowledgements

Not applicable.

### Funding

This work was supported by grants from the South African National Research Foundation (NRF) and from the Department of Science and Technology, South African Research Chair Initiative (SARCHI) and South Africa Medical Research Council (SAMRC) to FB, grant from the Japan Society for the Promotion of Science (JSPS) and National Research Foundation of South Africa to FB and HS, grants from the South African National Research Foundation (NRF) Competitive Programme for Unrated Researchers (CSUR) to RG, and Massey University Doctoral Research Dissemination Grant from Massey University, New Zealand to ED. The funders had no role in the study design, data collection, analysis, and interpretation, or in writing the manuscript.

### Availability of data and materials

The dataset analysed in the study is available in the FANTOM5 repository, [http://fantom.gsc.riken.jp/5/datafiles/reprocessed/mm10\\_v2/basic/](http://fantom.gsc.riken.jp/5/datafiles/reprocessed/mm10_v2/basic/). The datasets supporting the conclusions of this article are included within the article and its additional files.

### Authors' contributions

ED performed computational analyses. SS designed the study. RG and HS performed the experiments. SS and ED analysed data, interpreted results, and wrote the manuscript with input from all authors. RG, MM, HS, and FB helped interpret results and provided data. All authors read and approved the final manuscript.

### Ethics approval and consent to participate

Mice were sacrificed in accordance with the Animal Research Ethics of South African National Standard (SANS 10386:2008) and University of Cape Town of practice for laboratory animal procedures. The protocol (Permit Number: 012/036) was approved by the Animal Ethics Committee, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

### Consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

### Author details

<sup>1</sup>Massey University, Institute of Natural and Mathematical Sciences, Albany, Auckland, New Zealand. <sup>2</sup>Division of Immunology and South African Medical Research Council (SAMRC) Immunology of Infectious Diseases, Faculty of Health Sciences, Institute of Infectious Diseases and Molecular Medicine (IDM), University of Cape Town, Cape Town, South Africa. <sup>3</sup>International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town Component, Cape Town, South Africa. <sup>4</sup>Gene Expression and Biophysics Group, CSIR Synthetic Biology ERA, Pretoria, South Africa. <sup>5</sup>Division of Chemical Systems and Synthetic Biology, Institute of Infectious Diseases and Molecular Medicine (IDM), University of Cape Town, Cape Town, South Africa. <sup>6</sup>Gene Expression and Biophysics Unit, Instituto de Medicina Molecular, Faculdade de Medicina Universidade de Lisboa, Lisbon, Portugal. <sup>7</sup>Division of Genomic Technologies, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Japan.

Received: 2 September 2018 Accepted: 11 January 2019

Published online: 22 January 2019

### References

- Xu G, Wang J, Gao GF, Liu CH. Insights into battles between *Mycobacterium tuberculosis* and macrophages. *Protein Cell*. 2014;5:728–36.
- Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. *N Engl J Med*. 2013;368:745–55.
- Weiss G, Schaible UE. Macrophage defense mechanisms against intracellular bacteria. *Immunol Rev*. 2015;264:182–203.
- Orme IM, Robinson RT, Cooper AM. The balance between protective and pathogenic immune responses in the TB-infected lung. *Nat Immunol*. 2015;16:57–63.
- Guirado E, Schlesinger L, Kaplan G. Macrophages in tuberculosis: friend or foe. *Semin Immunopathol*. 2013;35:563–83.
- Komili S, Silver PA. Coupling and coordination in gene expression processes: a systems biology view. *Nat Rev Genet*. 2008;9:38–48.
- Weake VM, Workman JL. Inducible gene expression: diverse regulatory mechanisms. *Nat Rev Genet*. 2010;11:426–37.
- Shlyueva D, Stampfel G, Stark A. Transcriptional enhancers: from properties to genome-wide predictions. *Nat Rev Genet*. 2014;15:272–86.
- Romanoski CE, Link VM, Heinz S, Glass CK. Exploiting genomics and natural genetic variation to decode macrophage enhancers. *Trends Immunol*. 2015;36:507–18.
- Kieffer-Kwon KR, Tang Z, Mathe E, Qian J, Sung MH, Li G, et al. Interactome maps of mouse gene regulatory domains reveal basic principles of transcriptional regulation. *Cell*. 2013;155:1507–20.
- Li W, Notani D, Rosenfeld MG. Enhancers as non-coding RNA transcription units: recent insights and future perspectives. *Nat Rev Genet*. 2016;17:207–23.
- Creyghton MP, Cheng AW, Welstead GG, Kooistra T, Carey BW, Steine EJ, et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. *Proceedings of the National Academy of Sciences, USA*. 2010;107:21931–6.
- Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, Harp LF, et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. *Nature*. 2009;459:108–12.
- Spitz F, Furlong EE. Transcription factors: from enhancer binding to developmental control. *Nat Rev Genet*. 2012;13:613–26.
- Koch F, Fenouil R, Gut M, Cauchy P, Albert TK, Zacarias-Cabeza J, et al. Transcription initiation platforms and GTF recruitment at tissue-specific enhancers and promoters. *Nat Struct Mol Biol*. 2011;18:956–63.
- Kim TK, Hemberg M, Gray JM, Costa AM, Bear DM, Wu J, et al. Widespread transcription at neuronal activity-regulated enhancers. *Nature*. 2010;465:182–7.
- Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J, Boyd M, et al. An atlas of active enhancers across human cell types and tissues. *Nature*. 2014;507:455–61.
- Sanyal A, Lajoie B, Jain G, Dekker J. The long-range interaction landscape of gene promoters. *Nature*. 2012;489:109–13.
- Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y, et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. *Nature*. 2011;474:390–4.
- Wu H, Nord AS, Akiyama JA, Shoukry M, Afzal V, Rubin EM, et al. Tissue-specific RNA expression Marks distant-acting developmental enhancers. *PLoS Genet*. 2014;10:12.
- Mikhaylichenko O, Bondarenko V, Harnett D, Schor IE, Males M, Viales RR, et al. The degree of enhancer or promoter activity is reflected by the levels and directionality of eRNA transcription. *Genes Dev*. 2018;32(1):42–57.
- De Santa F, Barozzi I, Mietton F, Ghisletti S, Polletti S, Tusi BK, et al. A large fraction of extragenic RNA pol II transcription sites overlap enhancers. *PLoS Biol*. 2010;8:e1000384.
- Natoli G, Andrau JC. Noncoding transcription at enhancers: general principles and functional models. *Annu Rev Genet*. 2012;46:1–19.
- Lam MT, Li W, Rosenfeld MG, Glass CK. Enhancer RNAs and regulated transcriptional programs. *Trends Biochem Sci*. 2014;39:170–82.
- Melgar MF, Collins FS, Sethupathy P. Discovery of active enhancers through bidirectional expression of short transcripts. *Genome Biol*. 2011;12:R113.
- Core LJ, Martins AL, Danko CG, Waters CT, Siepel A, Lis JT. Analysis of nascent RNA identifies a unified architecture of initiation regions at mammalian promoters and enhancers. *Nat Genet*. 2014;46:1311–20.
- Rocha PP, Raviram R, Bonneau R, Skok JA. Breaking TADs: insights into hierarchical genome organization. *EpiGenomics*. 2015;7:523–6.
- Dixon JR, Selvaraj S, Yue F, Kim A, Li Y, Shen Y, et al. Topological domains in mammalian genomes identified by analysis of chromatin interactions. *Nature*. 2012;485:376–80.
- Lupianez DG, Spielmann M, Mundlos S. Breaking TADs: how alterations of chromatin domains result in disease. *Trends Genet*. 2016;32:225–37.
- Beagrie RA, Pombo A. Gene activation by metazoan enhancers: diverse mechanisms stimulate distinct steps of transcription. *BioEssays*. 2016;38:881–93.

31. Osterwalder M, Barozzi I, Tissieres V, Fukuda-Yuzawa Y, Mannion BJ, Afzal SY, et al. Enhancer redundancy provides phenotypic robustness in mammalian development. *Nature*. 2018;554:239–43.
32. Heinz S, Romanoski CE, Benner C, Glass CK. The selection and function of cell type-specific enhancers. *Nat Rev Mol Cell Biol*. 2015;16:144–54.
33. Denisenko E, Guler R, Mhlanga MM, Suzuki H, Brombacher F, Schmeier S. Genome-wide profiling of transcribed enhancers during macrophage activation. *Epigenetics Chromatin*. 2017;10:50.
34. Hah N, Benner C, Chong LW, Yu RT, Downes M, Evans RM. Inflammation-sensitive super enhancers form domains of coordinately regulated enhancer RNAs. *Proceedings of the National Academy of Sciences, USA*. 2015;112: E297–302.
35. Witte S, O'Shea JJ, Vahedi G. Super-enhancers: Asset management in immune cell genomes. *Trends Immunol*. 2015;36:519–26.
36. Pott S, Lieb JD. What are super-enhancers? *Nat Genet*. 2015;47:8–12.
37. Balcewicz-Sablinska MK, Keane J, Kornfeld H, Remold HG. Pathogenic *Mycobacterium tuberculosis* evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-alpha. *J Immunol*. 1998; 161:2636–41.
38. Siegmund D, Kums J, Ehrenschrwender M, Wajant H. Activation of TNFR2 sensitizes macrophages for TNFR1-mediated necroptosis. *Cell Death Dis*. 2016;7:e2375.
39. Michelucci A, Cordes T, Ghelfi J, Pailot A, Reiling N, Goldmann O, et al. Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production. *Proc Natl Acad Sci U S A*. 2013;110: 7820–5.
40. Mamo A, Jules F, Dumaresq-Doiron K, Costantino S, Lefrancois S. The role of ceroid lipofuscinosis neuronal protein 5 (CLN5) in endosomal sorting. *Mol Cell Biol*. 2012;32:1855–66.
41. Seto S, Tsujimura K, Koide Y. Rab GTPases regulating phagosome maturation are differentially recruited to mycobacterial phagosomes. *Traffic*. 2011;12:407–20.
42. Harrison RE, Bucci C, Vieira OV, Schroer TA, Grinstein S. Phagosomes fuse with late endosomes and/or lysosomes by extension of membrane protrusions along microtubules: role of Rab7 and RILP. *Mol Cell Biol*. 2003; 23:6494–506.
43. Via LE, Deretic D, Ulmer RJ, Hibler NS, Huber LA, Deretic V. Arrest of mycobacterial phagosome maturation is caused by a block in vesicle fusion between stages controlled by rab5 and rab7. *J Biol Chem*. 1997;272:13326–31.
44. Maier A, Wu H, Cordasic N, Oefner P, Dietel B, Thiele C, et al. Hypoxia-inducible protein 2 Hlg2/Hilpda mediates neutral lipid accumulation in macrophages and contributes to atherosclerosis in apolipoprotein E-deficient mice. *FASEB J*. 2017;31:4971–84.
45. Daniel J, Maamar H, Deb C, Sirakova TD, Kolattukudy PE. *Mycobacterium tuberculosis* uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages. *PLoS Pathog*. 2011;7:e1002093.
46. Mu D, Cambier S, Fjellbirkeland L, Baron JL, Munger JS, Kawakatsu H, et al. The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. *J Cell Biol*. 2002;157:493–507.
47. Reed SG. TGF-beta in infections and infectious diseases. *Microbes Infect*. 1999;1:1313–25.
48. Iqbal J, Zaidi M. TNF regulates cellular NAD+ metabolism in primary macrophages. *Biochem Biophys Res Commun*. 2006;342:1312–8.
49. Kang J, Park KH, Kim JJ, Jo EK, Han MK, Kim UH. The role of CD38 in Fc gamma receptor (Fc gammaR)-mediated phagocytosis in murine macrophages. *J Biol Chem*. 2012;287:14502–14.
50. Botta D, Rivero-Nava L, Lund F. The NAD glycohydrolase CD38 regulates macrophage effector function and defense against listeria monocytogenes. (INC7P.409). *The J Immunol*. 2014;192:186.10.
51. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. *Annu Rev Immunol*. 2014; 32:659–702.
52. Karlstetter M, Walczak Y, Weigelt K, Ebert S, Van den Brulle J, Schwer H, et al. The novel activated microglia/macrophage WAP domain protein, AMWAP, acts as a counter-regulator of proinflammatory response. *J Immunol*. 2010; 185:3379–90.
53. Fratti RA, Backer JM, Gruenberg J, Corvera S, Deretic V. Role of phosphatidylinositol 3-kinase and Rab5 effectors in phagosomal biogenesis and mycobacterial phagosome maturation arrest. *J Cell Biol*. 2001;154:631–44.
54. Fontana MF, Baccarella A, Pancholi N, Pufall MA, Herbert DR, Kim CC. JUNB is a key transcriptional modulator of macrophage activation. *J Immunol*. 2015;194:177–86.
55. Roy S, Guler R, Parihar SP, Schmeier S, Kaczowski B, Nishimura H, et al. Batf2/Irf1 induces inflammatory responses in classically activated macrophages, lipopolysaccharides, and mycobacterial infection. *J Immunol*. 2015;194:6035–44.
56. Schorey JS, Cooper AM. Macrophage signalling upon mycobacterial infection: the MAP kinases lead the way. *Cell Microbiol*. 2003;5:133–42.
57. Oviedo-Boyo J, Bravo-Patino A, Baizabal-Aguirre VM. Collaborative action of toll-like and NOD-like receptors as modulators of the inflammatory response to pathogenic bacteria. *Mediat Inflamm*. 2014;2014:432785.
58. Shang Y, Smith S, Hu X. Role of notch signaling in regulating innate immunity and inflammation in health and disease. *Protein Cell*. 2016;7:159–74.
59. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. *Annu Rev Pharmacol Toxicol*. 2007;47:89–116.
60. Harvey CJ, Thimmulappa RK, Sethi S, Kong X, Yarmus L, Brown RH, et al. Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model. *Sci Transl Med*. 2011;3:78ra32.
61. Ostuni R, Piccolo V, Barozzi I, Polletti S, Termanini A, Bonifacio S, et al. Latent enhancers activated by stimulation in differentiated cells. *Cell*. 2013;152:157–71.
62. Behar SM, Divangahi M, Remold HG. Evasion of innate immunity by *Mycobacterium tuberculosis*: is death an exit strategy? *Nat Rev Microbiol*. 2010;8:668–74.
63. Correa AF, Bailao AM, Bastos IM, Orme IM, Soares CM, Kipnis A, et al. The endothelin system has a significant role in the pathogenesis and progression of *Mycobacterium tuberculosis* infection. *Infect Immun*. 2014;82: 5154–65.
64. Rottenberg ME, Carow B. SOCS3 and STAT3, major controllers of the outcome of infection with *Mycobacterium tuberculosis*. *Semin Immunol*. 2014;26:518–32.
65. Rehli M, Sulzbacher S, Pape S, Ravasi T, Wells CA, Heinz S, et al. Transcription factor Tfec contributes to the IL-4-inducible expression of a small group of genes in mouse macrophages including the granulocyte colony-stimulating factor receptor. *J Immunol*. 2005;174:7111–22.
66. Ouimet M, Koster S, Sakowski E, Ramkhalawon B, van Solingen C, Oldebeken S, et al. *Mycobacterium tuberculosis* induces the miR-33 locus to reprogram autophagy and host lipid metabolism. *Nat Immunol*. 2016;17: 677–86.
67. Lecellier CH, Wasserman WW, Mathelier A. Human enhancers harboring specific sequence composition, activity, and Genome organization are linked to the immune response. *Genetics*. 2018;209:1055–71.
68. Chepelev I, Wei G, Wangsa D, Tang Q, Zhao K. Characterization of genome-wide enhancer-promoter interactions reveals co-expression of interacting genes and modes of higher order chromatin organization. *Cell Res*. 2012;22: 490–503.
69. Kaikkonen MU, Spann NJ, Heinz S, Romanoski CE, Allison KA, Stender JD, et al. Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. *Mol Cell*. 2013;51:310–25.
70. Mukhopadhyay S, Ramadass AS, Akoulitchev A, Gordon S. Formation of distinct chromatin conformation signatures epigenetically regulate macrophage activation. *Int Immunopharmacol*. 2014;18:7–11.
71. Factor DC, Corradin O, Zentner GE, Saiakhova A, Song L, Chenoweth JG, et al. Epigenomic comparison reveals activation of 'seed' enhancers during transition from naive to primed pluripotency. *Cell Stem Cell*. 2014;14:854–63.
72. Shin HY, Willi M, HyunYoo K, Zeng X, Wang C, Metser G, et al. Hierarchy within the mammary STAT5-driven Wap super-enhancer. *Nat Genet*. 2016; 48:904–11.
73. Hmama Z, Pena-Diaz S, Joseph S, Av-Gay Y. Immuno-evasion and immunosuppression of the macrophage by *Mycobacterium tuberculosis*. *Immunol Rev*. 2015;264:220–32.
74. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. *Clin Microbiol Rev*. 2009;22:240–73.
75. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. *Oncogene*. 2004;23:2838–49.
76. Amaral EP, Lasunskaja EB, D'Imperio-Lima MR. Innate immunity in tuberculosis: how the sensing of mycobacteria and tissue damage modulates macrophage death. *Microbes Infect*. 2016;18:11–20.

77. Mayer-Barber KD, Sher A. Cytokine and lipid mediator networks in tuberculosis. *Immunol Rev.* 2015;264:264–75.
78. Gordon S, Pluddemann A. Tissue macrophages: heterogeneity and functions. *BMC Biol.* 2017;15:53.
79. Andreu N, Phelan J, de Sessions PF, Cliff JM, Clark TG, Hibberd ML. Primary macrophages and J774 cells respond differently to infection with *Mycobacterium tuberculosis*. *Sci Rep.* 2017;7:42225.
80. Wang C, Yu X, Cao Q, Wang Y, Zheng G, Tan TK, et al. Characterization of murine macrophages from bone marrow, spleen and peritoneum. *BMC Immunol.* 2013;14:6.
81. Herbst S, Schaible UE, Schneider BE. Interferon gamma activated macrophages kill mycobacteria by nitric oxide induced apoptosis. *PLoS One.* 2011;6:e19105.
82. Arora G, Misra R, Sajid A. Model Systems for Pulmonary Infectious Diseases: paradigms of Anthrax and tuberculosis. *Curr Top Med Chem.* 2017;17:2077–99.
83. Das A, Yang CS, Arifuzzaman S, Kim S, Kim SY, Jung KH, et al. High-resolution mapping and dynamics of the transcriptome, transcription factors, and transcription co-Factor networks in classically and alternatively activated macrophages. *Front Immunol.* 2018;9:22.
84. Jablonski KA, Amici SA, Webb LM, Ruiz-Rosado Jde D, Popovich PG, Partida-Sanchez S, et al. Novel markers to delineate murine M1 and M2 macrophages. *PLoS One.* 2015;10:e0145342.
85. Sedlyarov V, Fallmann J, Ebner F, Huemer J, Sneezum L, Ivin M, et al. Tristetraprolin binding site atlas in the macrophage transcriptome reveals a switch for inflammation resolution. *Mol Syst Biol.* 2016;12:868.
86. Kiran D, Podell BK, Chambers M, Basaraba RJ. Host-directed therapy targeting the *Mycobacterium tuberculosis* granuloma: a review. *Semin Immunopathol.* 2016;38:167–83.
87. Wallis RS, Hafner R. Advancing host-directed therapy for tuberculosis. *Nat Rev Immunol.* 2015;15:255–63.
88. Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. *Cell.* 2013;153:320–34.
89. Peeters JG, Vervoort SJ, Tan SC, Mijnheer G, de Roock S, Vastert SJ, et al. Inhibition of super-enhancer activity in autoinflammatory site-derived T cells reduces disease-associated gene expression. *Cell Rep.* 2015;12:1986–96.
90. Roy S, Schmeier S, Arner E, Alam T, Parihar SP, Ozturk M, et al. Redefining the transcriptional regulatory dynamics of classically and alternatively activated macrophages by deepCAGE transcriptomics. *Nucleic Acids Res.* 2015;43:6969–82.
91. Koo MS, Subbian S, Kaplan G. Strain specific transcriptional response in *Mycobacterium tuberculosis* infected macrophages. *Cell Commun Signal.* 2012;10:2.
92. Roy S, Schmeier S, Kaczowski B, Arner E, Alam T, Ozturk M, et al. Transcriptional landscape of *Mycobacterium tuberculosis* infection in macrophages. *Sci Rep.* 2018;8:6758.
93. Flicek P, Amode MR, Barrell D, Beal K, Brent S, Chen Y, et al. Ensembl 2011. *Nucleic Acids Res.* 2011;39:D800–D6.
94. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics.* 2010;26:139–40.
95. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Ser B Methodol.* 1995;57:289–300.
96. Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. *Nucleic Acids Res.* 2000;28:27–30.
97. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res.* 2009;37:1–13.
98. UCSC Genome Browser Utilities: Batch Coordinate Conversion (liftOver). <https://genome.ucsc.edu/cgi-bin/hgLiftOver>. Accessed 15 Sept 2016.
99. Khan A, Fornes O, Stigliani A, Gheorghe M, Castro-Mondragon JA, van der Lee R, et al. JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework. *Nucleic Acids Res.* 2018;46(D1):D260–D266.
100. Frith MC, Fu Y, Yu L, Chen JF, Hansen U, Weng Z. Detection of functional DNA motifs via statistical over-representation. *Nucleic Acids Res.* 2004;32:1372–81.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

